Lista de obras - Mario Nuvolone - Dominio Público Uruguay

A neuroprotective role for microglia in prion diseases

artículo científico publicado en 2016

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

artículo científico publicado en 2012

Altered Monoaminergic Systems and Depressive-like Behavior in Congenic Prion Protein Knock-out Mice

artículo científico publicado en 2015

Cells and prions: a license to replicate

scientific article published on 13 June 2009

Cystatin F is a biomarker of prion pathogenesis in mice

artículo científico publicado en 2017

Efficient amyloid A clearance in the absence of immunoglobulins and complement factors

artículo científico publicado en 2013

Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture

artículo científico publicado en 2010

Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney

artículo científico publicado en 2016

Extended characterization of the novel co-isogenic C57BL/6J Prnp-/- mouse line

artículo científico publicado en 2017

Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis

artículo científico publicado en 2024

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

artículo científico publicado en 2017

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

artículo científico publicado en 2009

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

artículo científico publicado en 2014

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

artículo científico publicado en 2013

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

artículo científico publicado en 2017

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis

artículo científico publicado en 2017

Prion pathogenesis in the absence of NLRP3/ASC inflammasomes

artículo científico publicado en 2015

Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier

artículo científico publicado en 2018

Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling

artículo científico publicado en 2017

Prion protein and Abeta-related synaptic toxicity impairment

artículo científico publicado en 2010

Prognostication of survival and progression to dialysis in AA amyloidosis

artículo científico publicado en 2017

Regulated expression of amyloidogenic immunoglobulin light chains in mice

SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells

artículo científico publicado en 2013

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

artículo científico publicado en 2011

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response

artículo científico publicado en 2017

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients

artículo científico publicado en 2019

Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science

artículo científico publicado en 2016

Structure-based drug design identifies polythiophenes as antiprion compounds

artículo científico publicado en 2015

Systemic amyloidosis: novel therapies and role of biomarkers

artículo científico publicado en 2016

The Priority position paper: Protecting Europe's food chain from prions

artículo científico publicado en 2016

The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease

artículo científico publicado en 2012

The immunobiology of prion diseases

artículo científico publicado en 2013

The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6

scientific journal article

The role of the NADPH oxidase NOX2 in prion pathogenesis

artículo científico publicado en 2014

The workings of the amyloid diseases

artículo científico publicado en 2007

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

artículo científico publicado en 2008

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

scientific article published on 01 July 2007

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis

artículo científico publicado en 2017

Lista de obras de Mario Nuvolone

A neuroprotective role for microglia in prion diseases

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

Altered Monoaminergic Systems and Depressive-like Behavior in Congenic Prion Protein Knock-out Mice

Cells and prions: a license to replicate

Cystatin F is a biomarker of prion pathogenesis in mice

Efficient amyloid A clearance in the absence of immunoglobulins and complement factors

Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture

Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney

Extended characterization of the novel co-isogenic C57BL/6J Prnp-/- mouse line

Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis

Prion pathogenesis in the absence of NLRP3/ASC inflammasomes

Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier

Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling

Prion protein and Abeta-related synaptic toxicity impairment

Prognostication of survival and progression to dialysis in AA amyloidosis

Regulated expression of amyloidogenic immunoglobulin light chains in mice

SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients

Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science

Structure-based drug design identifies polythiophenes as antiprion compounds

Systemic amyloidosis: novel therapies and role of biomarkers

The Priority position paper: Protecting Europe's food chain from prions

The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease

The immunobiology of prion diseases

The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6

The role of the NADPH oxidase NOX2 in prion pathogenesis

The workings of the amyloid diseases

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis